. 2021 May 23;13(6):1782. doi: 10.3390/nu13061782

Table 2.

Data extraction format for studies included to compute the prevalence of MetS in children with T1DM.

Author	Country	Sample Size Total (F/M)	Age (Year)	Duration of T1DM (Years)	HbA1c (%)	Over- Weight	Obesity	Diagnosis of MetS		Components of MetS
		Sample Size Total (F/M)	Age (Year)	Duration of T1DM (Years)	HbA1c (%)	Over- Weight	Obesity	Total	F/M	Ab. Obesity	Low HDL	High TG	High BP
		n	Min–Max	$\bar{x}$ ± SD Me (IQR)	$\bar{x}$ ± SD Me (IQR)	n (%)		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Castro-Correia [14]	Portugal	42	14–18	9.2±3.6	8.6±1	18		n/d	n/d	17 (40.5%)	7 (16.7%)	4 (9.5%)	7 (16.7%)
Castro-Correia [14]	Portugal	(42/-)	14–18	9.2±3.6	8.6±1	(42.9%)		n/d	n/d	17 (40.5%)	7 (16.7%)	4 (9.5%)	7 (16.7%)
Köken [15]	Turkey	200	8–18	4.6 ± 3.3	8.4 ± 1.6	19	17	17 (8.5%) ^WHO	11 (11.5%)	n/d	n/d	n/d	24 (12.0%)
		(96/104)				(9.5%)	(8.5%)	21 (10.5%) ^IDF	/10 (9.6%)
								27 (13.5%) ^ATP
Łuczyński [16]	Poland	500	4–18	4.4 (2.1–7.0)	n/a	78 (15.6%)	73 (14.6%)	16 (3.2%) ^IDF	n/d	67 (13.4%)	32 (6.4%)	31 (6.2%)	24 (4.8%)
Łuczyński [16]	Poland	(245/255)	4–18	4.4 (2.1–7.0)	n/a	78 (15.6%)	73 (14.6%)	16 (3.2%) ^IDF	n/d	67 (13.4%)	32 (6.4%)	31 (6.2%)	24 (4.8%)
Saki [17]	Iran	87	4–21	8.0 ± 3.9	8 ± 3	n/d	n/d	21 (24.1%) ^IDF	11 (23.2%) /10 (24.8%)	6 (6.0%)	32 (36.8%)	32 (36.8%)	13 (14.9%)
Saki [17]	Iran	(48/39)	4–21	8.0 ± 3.9	8 ± 3	n/d	n/d	21 (24.1%) ^IDF	11 (23.2%) /10 (24.8%)	6 (6.0%)	32 (36.8%)	32 (36.8%)	13 (14.9%)
Saki [18]	Iran	87	4–21	8.0 ± 3.9	8 ± 3	n/d	n/d	26 (29.9%) ^ATP	14 (29.2%) /12 (30.7%)	1 (1.1%)	33 (41.7%)	48 (55.2%)	13 (14.9%)
Saki [18]	Iran	(48/39)	4–21	8.0 ± 3.9	8 ± 3	n/d	n/d	26 (29.9%) ^ATP	14 (29.2%) /12 (30.7%)	1 (1.1%)	33 (41.7%)	48 (55.2%)	13 (14.9%)
Soliman [19]	Egypt	160	<18	5.7 ± 3	9 ± 2.2	n/d	n/d	21 (13.1%) ^IDF	15 (18.1%) /6 (7.8%)	n/d	n/d	n/d	n/d
Soliman [19]	Egypt	(83/77)	<18	5.7 ± 3	9 ± 2.2	n/d	n/d	21 (13.1%) ^IDF	15 (18.1%) /6 (7.8%)	n/d	n/d	n/d	n/d
Szadkowska [20]	Poland	163	10–18	6.2 ± 4.2	8 ± 1.5	n/d	n/d	14 (8.6%) ^IDF	8 (11.1%) /6 (6.6%)	32 (19.6%)	4 (2.5%)	14 (8.6%)	33 (20.3%)
Szadkowska [20]	Poland	(72/91)	10–18	6.2 ± 4.2	8 ± 1.5	n/d	n/d	14 (8.6%) ^IDF	8 (11.1%) /6 (6.6%)	32 (19.6%)	4 (2.5%)	14 (8.6%)	33 (20.3%)
Van Vliet [21]	The Netherlands	283	3–18	5.3 (2.9–8.6)	8.3 (7.5–9.8)	83 (29.3%)	26 (9.2%)	81 (28.6%) ^WEISS	n/d	26 (9.2%)	60 (21.2%)	49 (17.3%)	37 (13.1%)
Van Vliet [21]	The Netherlands	(145/138)	3–18	5.3 (2.9–8.6)	8.3 (7.5–9.8)	83 (29.3%)	26 (9.2%)	81 (28.6%) ^WEISS	n/d	26 (9.2%)	60 (21.2%)	49 (17.3%)	37 (13.1%)
Valerio [22]	Italy	412	16–19	8.4 ± 3.9	8.9 ± 1.7	101 (24.5%)	16 (3.9%)	39 (9.5%) ^IDF	31 (16.1%) /8 (3.7%)	83 (20.1%)	66 (16.0%)	23 (5.6%)	73 (17.7%)
Valerio [22]	Italy	(193/219)	16–19	8.4 ± 3.9	8.9 ± 1.7	101 (24.5%)	16 (3.9%)	39 (9.5%) ^IDF	31 (16.1%) /8 (3.7%)	83 (20.1%)	66 (16.0%)	23 (5.6%)	73 (17.7%)

Abbreviations: abdominal (Ab), National Cholesterol Education Program Adult Treatment Panel III (ATP), blood pressure (BP), females (F), high-density lipoprotein (HDL), International Diabetes Federation (IDF), interquartile range (IQR), males (M), median (Me), no data (n/d), number of participants (n), metabolic syndrome (MetS), standard deviation (SD), type 1 diabetes mellitus (T1DM), triglycerides (TG), World Health Organization (WHO), mean ( $\bar{x})$ .